clinical development – Page 7 – Communicable Diseases Research

Development of an Inactivated Vaccine against SARS CoV-2

SARS COV-2에 대한 불활성 백신의 개발

Article

Published on 2021-11-022022-09-10
Journal: Vaccines [Category] 비임상,

Accelerating vaccine trial conduct in a pandemic with a hot spot-based inclusion strategy using trial and epidemic simulation

시험 및 전염병 시뮬레이션을 사용하여 핫스팟 기반 포함 전략으로 전염병에서 백신 시험 수행 가속화

Article

Published on 2021-11-012022-09-11
Journal: Clinical and translational science [Category] SARS, 임상,

Crocetin and related oxygen diffusion-enhancing compounds: Review of chemical synthesis, pharmacology, clinical development, and novel therapeutic applications

크로세틴 및 관련 산소 확산 강화 화합물: 화학 합성, 약리학, 임상 개발 및 새로운 치료 응용 프로그램 검토

Review

Published on 2021-11-012022-09-11
Journal: Drug development research [Category] 임상,

Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

IgG-Fc 융합 코로나19 서브유닛 백신 AKS-452 개발

Article

Published on 2021-10-292022-09-11
Journal: Vaccine [Category] MERS, SARS, 변종, 진단,

[키워드] adjuvant adjuvants African Antigen APCS augmentation B.1.351 Cell cells clinical development Clinical studies clinical study clinical symptom Clinical symptoms comparable coronavirus COVID-19 COVID-19 pandemic development dose doses ENhance evaluated expectation Fc-fusion FcγR fusion protein greater huACE2 human IgG1 Fc IgG titers immunogenic immunogenicity Infection Infectious disease K18 live SARS-CoV-2 maintain mice Neonatal neutralization neutralizing IgG titer Neutralizing titer NHP NHPs non-human primate non-human primates pandemic phase preclinical studies preclinical study Prophylaxis receptor Receptor binding domain Region SARS-CoV-2 viral infection SARS-CoV-2 virus single dose South Spike protein subunit Subunit vaccine Support the SARS-CoV-2 USA-WA1/2020 Vaccine Vero-E6 cells Viral viral infection viral spike protein viral strain viral variant virus virus infection
[DOI] 10.1016/j.vaccine.2021.09.077 PMC 바로가기 [Article Type] Article

Brain cross‐protection against SARS‐CoV‐2 variants by a lentiviral vaccine in new transgenic mice

새로운 형질전환 마우스에서 렌티바이러스 백신에 의한 SARS-CoV-2 변이체에 대한 뇌 교차 보호

Article

Published on 2021-10-252022-09-11
Journal: EMBO Molecular Medicine [Category] MERS, SARS, 변종, 진단,

[키워드] accumulated addition angiotensin boost Brain caused Central nervous system clinical development COVID‐19 demonstrated displaying Efficacy elicit enzyme expressing Gamma hACE2 transgenic mice Immunity immunology induce intramuscular intranasal intranasal vaccination lentiviral lung mechanism Microbiology, Virology & Host Pathogen Interaction Mutation mutations neurological Neutralizing antibodies olfactory bulb P.1 PROTECT Protective reduced Replication robust SARS‐CoV‐2 SARS‐CoV‐2 emerging variants of concern spike glycoprotein T‐cell the vaccine transgenic mice transgenic model Transgenic mouse Vaccine vaccine candidate variant variants virus
[DOI] 10.15252/emmm.202114459 PMC 바로가기 [Article Type] Article

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

COVID19의 잠재적인 치료를 위한 정맥 코로나바이러스 3CL 프로테아제 억제제의 전임상 특성화

Article

Published on 2021-10-182022-09-10
Journal: Nature Communications [Category] MERS, SARS, 변종, 신약개발, 치료제,

A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells

새로운 종류의 TMPRSS2 억제제는 SARS-CoV-2 및 MERS-CoV 바이러스 진입을 강력하게 차단하고 인간 상피 폐 세포를 보호합니다

410

Published on 2021-10-112022-09-10
Journal: Proceedings of the National Academy of Sciences of [Category] MERS, SARS, 신약개발,

[키워드] activate acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Antiviral antiviral drug block broad-spectrum antivirals Calu Calu-3 calu-3 cells camostat can be used cell entry chimeric clinical development coronavirus COVID-19 COVID-19 treatment Cytopathic effect cytopathic effects drug drug candidate drug design Drug discovery drugs Efficacy epithelial epithelial cell epithelial cells full-length half-life half-maximal effective concentration half-maximal inhibitory concentration help host cell human lung in vivo Influenza influenza viruses inhibiting inhibitor lead lung lung cell lung tissue mechanism MERS-CoV mice Middle East Middle East respiratory syndrome Middle East respiratory syndrome Coronavirus nafamostat other coronavirus other coronaviruses Pathogenesis pharmacokinetics plasma probe protease Protease inhibitor PROTECT Protein PS-SCL respiratory respiratory syndrome coronavirus SARS-CoV SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 virus selective Serine serine protease TMPRSS2 severe acute respiratory syndrome Coronavirus Significance significantly specificity Spike protein stability structure-based drug discovery the Spike therapeutic target TMPRSS2 TMPRSS2 inhibitor TMPRSS2 inhibitors TMPRSS2 protein treat Treatment Viral viral entry viral pathogenesis Viral protein viral spread virus
[DOI] 10.1073/pnas.2108728118 PMC 바로가기 [Article Type] 410

SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques

Ad26.COV2.S 백신 접종 후 SARS-CoV-2 결합 및 중화 항체 수준은 붉은털 원숭이의 지속적인 보호를 예측합니다

Article

Published on 2021-10-072022-09-10
Journal: Nature Communications [Category] MERS, SARS, 변종, 진단,

[키워드] Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Analysis Antibody titer Antibody titers approval authorization binding clinical development COVID-19 vaccine Efficacy Emergency use Evidence Human Immunity immunization immunogenicity immunological indicate knowledge Limited lung Lungs macaque natural infection Neutralizing antibodies neutralizing antibody other coronavirus other coronaviruses post vaccination predict predicted Predictive markers preliminary evidence Protective Protein Replication replication of SARS-CoV-2 rhesus macaque rhesus macaques SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein selected short-lived spike Spike protein the SARS-CoV-2 vaccination Vaccine Vaccines variant vector viral infection
[DOI] 10.1038/s41467-021-26117-x PMC 바로가기 [Article Type] Article

Emerging therapeutic opportunities for integrin inhibitors

Reviews

Published on 2021-09-172022-10-05
Journal: Nature Reviews Drug Discovery [Category] 바이오마커,

COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions

COVID-19 팬데믹 및 백신 관련 과제 및 해결 방법 업데이트

Review

Published on 2021-09-102022-09-11
Journal: Frontiers in Cellular and Infection Microbiology [Category] MERS, SARS, 변종,

[키워드] ACE-2 receptor acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 all age group all age groups Alpha Antibody-dependent enhancement approach approval approved attenuated vaccine Attenuated Virus B.1.1.7 B.1.351 B.1.429 B.1.525 B.1.617 B.1.617.2 BCG being Beta booster dose candidate vaccine caused CD8 challenge China city clinical development clinical trial combating Compliance contrary Coronaviridae family coronavirus coronavirus disease Coronavirus-2 COVID-19 CTL Delta disease severity Effectiveness Efficacy elicit Emergency use Epsilon Eta Gamma herd immunity host cells immune activation immune response immune responses Immunity inactivated Inactivated Vaccines inhibit intracellular pathogen Live attenuated vaccine MOST Multiple multiple antigens multivariant vaccines Mutation mutations Neutralizing antibodies neutralizing antibody nucleic acids pandemic pathogen Phase III clinical trials platform potential limitations Prophylactic Replication Resolution RNA virus SARS CoV-2 variant SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Spike protein subunit vaccines T cell the Coronaviridae Vaccine vaccine candidate Vaccine hesitancy Vaccines variant variants Viral Viral antigen viral antigens viral entry viral spike protein viral vectors virus viruses WHO Wuhan
[DOI] 10.3389/fcimb.2021.690621 PMC 바로가기 [Article Type] Review